A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract

Myra L. Weiner, David Nuber, William R. Blakemore, Jay F. Harriman, Samuel Monroe Cohen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Groups of Fischer 344 rats (20/sex/group) received control or treated diets at levels of 0, 25,000 or 50,000 ppm kappa carrageenan with a molecular weight range (Mw) of 196,000-257,000 Da for 90 days. The Low Molecular Weight Tail (LMT) ranged between 1.9% and 12.0% < 50 kDa (mean 7%) based on the results of a program initiated to develop a validated analytical method to measure the LMT. This is the first GLP dietary study in which carrageenan is characterized by percentage LMT. Clinical examinations were performed daily. Individual food consumption/body weight measurements were made weekly. Ophthalmic exam was conducted prior to and at the end of treatment. Hematology/serum chemistry and urinalysis evaluations were done at necropsy, as were organ weight determinations for adrenals, brain, heart, kidneys, liver, ovaries, spleen, testes and thyroid with parathyroids. Full histopathological evaluation of organs was conducted on the control and 50,000 ppm groups, including hematoxylin-eosin-stained cross sections of paraffin-embedded rolled colon. Clinical signs were limited to soft feces in high dose rats and to a lesser extent in low dose rats. There were no treatment-related effects on body weights, urinalysis, hematology or clinical chemistry parameters, or on organ weights or ophthalmic, macroscopic or microscopic findings. The gastrointestinal tract appeared normal in detailed histopathological evaluation using the Swiss roll technique. The NOAEL is 50,000 ppm in the diet (mean calculated test material consumption of 3394 ± 706 mg/kg/day in males, 3867 ± 647 mg/kg/day in females). The results of the study provide evidence that it is not necessary to characterize carrageenan by a specification for LMT (less than 5% below 50 kDa) as has been done in Commission Directive 2004/45/EC of 16 April 2004 (Commission Directive, 2004/45/EC of 16 April 2004 amending Directive 96/77/EC laying down specific purity criteria on food additives other than colors and sweetners. Official Journal of European Union 20 April, 2004, L113/19-L113/21).

Original languageEnglish (US)
Pages (from-to)98-106
Number of pages9
JournalFood and Chemical Toxicology
Volume45
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

kappa carrageenan
Carrageenan
diet study techniques
gastrointestinal system
Gastrointestinal Tract
Molecular Weight
Molecular weight
Tail
molecular weight
tail
Rats
Urinalysis
urinalysis
Organ Size
carrageenan
Hematology
hematology
Nutrition
tissue weight
rats

Keywords

  • Carrageenan
  • Colon roll
  • Kappa carrageenan
  • Molecular weight
  • Subchronic toxicity

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Cite this

A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract. / Weiner, Myra L.; Nuber, David; Blakemore, William R.; Harriman, Jay F.; Cohen, Samuel Monroe.

In: Food and Chemical Toxicology, Vol. 45, No. 1, 01.01.2007, p. 98-106.

Research output: Contribution to journalArticle

Weiner, Myra L. ; Nuber, David ; Blakemore, William R. ; Harriman, Jay F. ; Cohen, Samuel Monroe. / A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract. In: Food and Chemical Toxicology. 2007 ; Vol. 45, No. 1. pp. 98-106.
@article{876500667ea1401d9ed0345a3edaff2b,
title = "A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract",
abstract = "Groups of Fischer 344 rats (20/sex/group) received control or treated diets at levels of 0, 25,000 or 50,000 ppm kappa carrageenan with a molecular weight range (Mw) of 196,000-257,000 Da for 90 days. The Low Molecular Weight Tail (LMT) ranged between 1.9{\%} and 12.0{\%} < 50 kDa (mean 7{\%}) based on the results of a program initiated to develop a validated analytical method to measure the LMT. This is the first GLP dietary study in which carrageenan is characterized by percentage LMT. Clinical examinations were performed daily. Individual food consumption/body weight measurements were made weekly. Ophthalmic exam was conducted prior to and at the end of treatment. Hematology/serum chemistry and urinalysis evaluations were done at necropsy, as were organ weight determinations for adrenals, brain, heart, kidneys, liver, ovaries, spleen, testes and thyroid with parathyroids. Full histopathological evaluation of organs was conducted on the control and 50,000 ppm groups, including hematoxylin-eosin-stained cross sections of paraffin-embedded rolled colon. Clinical signs were limited to soft feces in high dose rats and to a lesser extent in low dose rats. There were no treatment-related effects on body weights, urinalysis, hematology or clinical chemistry parameters, or on organ weights or ophthalmic, macroscopic or microscopic findings. The gastrointestinal tract appeared normal in detailed histopathological evaluation using the Swiss roll technique. The NOAEL is 50,000 ppm in the diet (mean calculated test material consumption of 3394 ± 706 mg/kg/day in males, 3867 ± 647 mg/kg/day in females). The results of the study provide evidence that it is not necessary to characterize carrageenan by a specification for LMT (less than 5{\%} below 50 kDa) as has been done in Commission Directive 2004/45/EC of 16 April 2004 (Commission Directive, 2004/45/EC of 16 April 2004 amending Directive 96/77/EC laying down specific purity criteria on food additives other than colors and sweetners. Official Journal of European Union 20 April, 2004, L113/19-L113/21).",
keywords = "Carrageenan, Colon roll, Kappa carrageenan, Molecular weight, Subchronic toxicity",
author = "Weiner, {Myra L.} and David Nuber and Blakemore, {William R.} and Harriman, {Jay F.} and Cohen, {Samuel Monroe}",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.fct.2006.07.033",
language = "English (US)",
volume = "45",
pages = "98--106",
journal = "Food and Chemical Toxicology",
issn = "0278-6915",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - A 90-day dietary study on kappa carrageenan with emphasis on the gastrointestinal tract

AU - Weiner, Myra L.

AU - Nuber, David

AU - Blakemore, William R.

AU - Harriman, Jay F.

AU - Cohen, Samuel Monroe

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Groups of Fischer 344 rats (20/sex/group) received control or treated diets at levels of 0, 25,000 or 50,000 ppm kappa carrageenan with a molecular weight range (Mw) of 196,000-257,000 Da for 90 days. The Low Molecular Weight Tail (LMT) ranged between 1.9% and 12.0% < 50 kDa (mean 7%) based on the results of a program initiated to develop a validated analytical method to measure the LMT. This is the first GLP dietary study in which carrageenan is characterized by percentage LMT. Clinical examinations were performed daily. Individual food consumption/body weight measurements were made weekly. Ophthalmic exam was conducted prior to and at the end of treatment. Hematology/serum chemistry and urinalysis evaluations were done at necropsy, as were organ weight determinations for adrenals, brain, heart, kidneys, liver, ovaries, spleen, testes and thyroid with parathyroids. Full histopathological evaluation of organs was conducted on the control and 50,000 ppm groups, including hematoxylin-eosin-stained cross sections of paraffin-embedded rolled colon. Clinical signs were limited to soft feces in high dose rats and to a lesser extent in low dose rats. There were no treatment-related effects on body weights, urinalysis, hematology or clinical chemistry parameters, or on organ weights or ophthalmic, macroscopic or microscopic findings. The gastrointestinal tract appeared normal in detailed histopathological evaluation using the Swiss roll technique. The NOAEL is 50,000 ppm in the diet (mean calculated test material consumption of 3394 ± 706 mg/kg/day in males, 3867 ± 647 mg/kg/day in females). The results of the study provide evidence that it is not necessary to characterize carrageenan by a specification for LMT (less than 5% below 50 kDa) as has been done in Commission Directive 2004/45/EC of 16 April 2004 (Commission Directive, 2004/45/EC of 16 April 2004 amending Directive 96/77/EC laying down specific purity criteria on food additives other than colors and sweetners. Official Journal of European Union 20 April, 2004, L113/19-L113/21).

AB - Groups of Fischer 344 rats (20/sex/group) received control or treated diets at levels of 0, 25,000 or 50,000 ppm kappa carrageenan with a molecular weight range (Mw) of 196,000-257,000 Da for 90 days. The Low Molecular Weight Tail (LMT) ranged between 1.9% and 12.0% < 50 kDa (mean 7%) based on the results of a program initiated to develop a validated analytical method to measure the LMT. This is the first GLP dietary study in which carrageenan is characterized by percentage LMT. Clinical examinations were performed daily. Individual food consumption/body weight measurements were made weekly. Ophthalmic exam was conducted prior to and at the end of treatment. Hematology/serum chemistry and urinalysis evaluations were done at necropsy, as were organ weight determinations for adrenals, brain, heart, kidneys, liver, ovaries, spleen, testes and thyroid with parathyroids. Full histopathological evaluation of organs was conducted on the control and 50,000 ppm groups, including hematoxylin-eosin-stained cross sections of paraffin-embedded rolled colon. Clinical signs were limited to soft feces in high dose rats and to a lesser extent in low dose rats. There were no treatment-related effects on body weights, urinalysis, hematology or clinical chemistry parameters, or on organ weights or ophthalmic, macroscopic or microscopic findings. The gastrointestinal tract appeared normal in detailed histopathological evaluation using the Swiss roll technique. The NOAEL is 50,000 ppm in the diet (mean calculated test material consumption of 3394 ± 706 mg/kg/day in males, 3867 ± 647 mg/kg/day in females). The results of the study provide evidence that it is not necessary to characterize carrageenan by a specification for LMT (less than 5% below 50 kDa) as has been done in Commission Directive 2004/45/EC of 16 April 2004 (Commission Directive, 2004/45/EC of 16 April 2004 amending Directive 96/77/EC laying down specific purity criteria on food additives other than colors and sweetners. Official Journal of European Union 20 April, 2004, L113/19-L113/21).

KW - Carrageenan

KW - Colon roll

KW - Kappa carrageenan

KW - Molecular weight

KW - Subchronic toxicity

UR - http://www.scopus.com/inward/record.url?scp=33751204748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751204748&partnerID=8YFLogxK

U2 - 10.1016/j.fct.2006.07.033

DO - 10.1016/j.fct.2006.07.033

M3 - Article

VL - 45

SP - 98

EP - 106

JO - Food and Chemical Toxicology

JF - Food and Chemical Toxicology

SN - 0278-6915

IS - 1

ER -